Cue Biopharma Inc (CUE)

05:15 AM

Cue Biopharma, Inc. (CUE) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance

05:15 AM

04:20 AM

Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights - Yahoo Finance

04:20 AM

Mar 24, 2025

Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights - The Manila Times

Mar 24, 2025

Mar 22, 2025

Bleichroeder LP Increases Stake in Cue Biopharma Inc - GuruFocus.com

Mar 22, 2025

Mar 21, 2025

[Top 3] Best Biotech Penny Stocks to Buy in 2025Finbold - Finbold - Finance in Bold

Mar 21, 2025

Mar 19, 2025

Cue Biopharma (CUE) Projected to Post Quarterly Earnings on Wednesday - Defense World

Mar 19, 2025

Mar 17, 2025

Strength Seen in TG Therapeutics (TGTX): Can Its 10.2% Jump Turn into More Strength? - Nasdaq

Mar 17, 2025

Mar 13, 2025

Cue Biopharma appoints Pasha Sarraf to board By Investing.com - Investing.com Australia

Mar 13, 2025

Mar 12, 2025

Cue Biopharma Appoints Pasha Sarraf to Board - TipRanks

Mar 12, 2025

Mar 12, 2025

Cue Biopharma appoints Pasha Sarraf to board - Investing.com

Mar 12, 2025

Mar 01, 2025

Cue Biopharma (NASDAQ:CUE) Trading Down 3.8%What's Next? - MarketBeat

Mar 01, 2025

Feb 24, 2025

Larger animals really are more prone to cancer, debunking ‘Peto’s paradox’ - Study Finds

Feb 24, 2025

Feb 21, 2025

Layoff Tracker: Spotlight Goes Dark After Disappointing Preclinical Data for CRISPR Platform - BioSpace

Feb 21, 2025

Feb 20, 2025

HPV+ Recurrent/Metastatic Head and Neck Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail

Feb 20, 2025

Feb 17, 2025

Public Ventures LLC Completes First Public Company Financing as a Broker-Dealer for Cue Biopharma, Inc. (Nasdaq:CUE) - ACCESS Newswire

Feb 17, 2025

Feb 12, 2025

Pancreatic Adenocarcinoma Market Growth Projections - openPR

Feb 12, 2025

Feb 05, 2025

Cue Biopharma, Inc. (NASDAQ:CUE) Short Interest Update - MarketBeat

Feb 05, 2025

Jan 31, 2025

Artiva Biotherapeutics expands board with industry veteran - MSN

Jan 31, 2025

Jan 30, 2025

Artiva Biotherapeutics Expands Board of Directors with Appointment of Dan Baker, M.D. - The Manila Times

Jan 30, 2025

Jan 29, 2025

Artiva Biotherapeutics appoints new director and committee members - MSN

Jan 29, 2025

Jan 29, 2025

Artiva Biotherapeutics appoints new director and committee members By Investing.com - Investing.com Nigeria

Jan 29, 2025

Jan 29, 2025

Artiva expands Board with appointment of Dan Baker, M.D - TipRanks

Jan 29, 2025

Jan 29, 2025

Former J&J Drug Development Chief Who Created Multi-Billion Dollar Therapies Joins Rising Biotech Board - StockTitan

Jan 29, 2025

Jan 13, 2025

Geode Capital Management LLC Increases Stock Position in Cue Biopharma, Inc. (NASDAQ:CUE) - Defense World

Jan 13, 2025

Jan 13, 2025

Geode Capital Management LLC Purchases 212,394 Shares of Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) - Defense World

Jan 13, 2025

Jan 06, 2025

HPV16+ Cancer Clinical and Non-Clinical Studies, Key - openPR

Jan 06, 2025

Jan 02, 2025

Cue Biopharma, Inc. (NASDAQ:CUE) Short Interest Up 8.0% in December - MarketBeat

Jan 02, 2025

Jan 02, 2025

Cue Biopharma (NASDAQ:CUE) versus FibroGen (NASDAQ:FGEN) Head-To-Head Comparison - Defense World

Jan 02, 2025

Dec 27, 2024

The definitive Boston biotech layoff tracker for 2024 - The Business Journals

Dec 27, 2024

Dec 25, 2024

Certain Common Stock of Cue Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 26-DEC-2024. - Marketscreener.com

Dec 25, 2024

Dec 19, 2024

Cue Biopharma CEO Daniel Passeri buys $30,900 in stock By Investing.com - Investing.com Australia

Dec 19, 2024

Dec 18, 2024

Cue Biopharma CEO Daniel Passeri buys $30,900 in stock - Investing.com India

Dec 18, 2024

Dec 18, 2024

Insider Buying: Daniel Passeri Acquires 30,000 Shares of Cue Bio - GuruFocus.com

Dec 18, 2024

Dec 18, 2024

Cue Biopharma, Inc. (NASDAQ:CUE) CEO Purchases $30,900.00 in Stock - MarketBeat

Dec 18, 2024

Dec 16, 2024

Short Interest in Cue Biopharma, Inc. (NASDAQ:CUE) Decreases By 6.5% - MarketBeat

Dec 16, 2024

Dec 13, 2024

Cue Biopharma's SWOT analysis: stock pivot to autoimmune focus sparks debate - Investing.com Australia

Dec 13, 2024

Nov 29, 2024

Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Nov 29, 2024

Nov 29, 2024

Cue Biopharma Grants 200,000 Share Option Award to New Development Chief - StockTitan

Nov 29, 2024

Nov 29, 2024

Amazon.com Inc (AMZN-Q) QuotePress Release - The Globe and Mail

Nov 29, 2024

Nov 29, 2024

Strong week for Cue Biopharma (NASDAQ:CUE) shareholders doesn't alleviate pain of five-year loss - Simply Wall St

Nov 29, 2024

Nov 25, 2024

Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference - The Manila Times

Nov 25, 2024

Nov 25, 2024

Cue Biopharma CEO to Present Clinical Updates at Piper Sandler Healthcare Conference | CUE Stock News - StockTitan

Nov 25, 2024

Nov 25, 2024

Cue Biopharma, Inc. (CUE) Reports Q3 Loss, Tops Revenue Estimates - MSN

Nov 25, 2024

Nov 25, 2024

Cue Biopharma, Inc. (NASDAQ:CUE) Shares Purchased by GSA Capital Partners LLP - Defense World

Nov 25, 2024